Skip to main content

Table 1 Baseline characteristics of the studies included in the meta-analysis

From: Association of circulating vaspin levels and patients with metabolic-associated fatty liver disease: a systematic review and meta-analysis

No.

Author

Year

Country

 

No. of Patients

Sex(F/M)

Age

BMI (kg/m2)

Detection Method

NAFLD

group

Control group

NAFLD

group

Control group

NAFLD

group

Control group

NAFLD

group

Control group

 

1

Aktas [25]

2011

Turkey

 

91

81

43/48

39/42

47 ± 9

46 ± 11

31.3 ± 5.1

26.5 ± 3.4

ELISA kit (Alpco Diagnostics, Salem, NH, USA)

2

Fu [26]

2019

China

 

188

100

101/87

53/47

48.26 ± 8.2

48.04 ± 7.2

21.65 ± 2.37

22.08 ± 2.25

ELISA kit (KLANG, Shanghai, China)

3

Genc [27]

2011

Turkey

 

50

30

50/0

30/0

32 ± 6

30 ± 5

28.5 ± 3.2

23.4 ± 2.9

ELISA kit (Catalog number 44-VASHU, Alpco Immu_x005fnoassays, Salem, NH, USA)

4

Ismail [24]

2019

Egypt

Total

30

15

5/25

2/13

/

41.8 ± 7.11

/

23.86 ± 2.19

ELISA kit

(Cat No. In- Hu3180: China Bioneovan Co., Ltd.)

SS

15

 

0/15

 

47.93 ± 4.31

 

34.59 ± 3.75

 

NASH

15

 

5/10

 

50.20 ± 9.10

 

34.33 ± 4.98

 

5

Kukla [28]

2010

Poland

 

41

20

26/15

10/10

45.7 ± 12.7

40.6 ± 5.5

30.4 ± 3.3

24.4 ± 4.1

ELISA kit (Catalogue No. V0712TP, AdipoGen

Inc., Seoul, South Korea)

6

Montazerifar [29]

2017

Iran

 

41

41

13/28

17/24

39.8 ± 8.9

36.7 ± 8.5

28.3 ± 4.2

25.1 ± 3.6

ELISA kit (Cat No. E2014Hu:

Shanghai Crystal Day Biotech Co., Ltd.)

7

Polyzos [30]

2016

Greece

Total

29

25

7/22

5/20

/

53.6 ± 1.8

/

30.5 ± 0.8

ELISA kit (RayBiotech, Norcross, GA, USA)

SS

15

 

5/10

 

53.9 ± 2.6

 

31.9 ± 1.3

 

NASH

14

 

2/12

 

54.8 ± 1.6

 

33.9 ± 1.6

 

8

Su [31]

2021

China

 

138

129

53/85

50/79

*a

42.7 ± 7.5

27.9 ± 4.6

23.1 ± 3.6

ELISA kit (JingTian, Shanghai, China)

9

Waluga [32]

2019

Poland

 

25

25

12/13

11/14

31 ± 10

42 ± 15

31.14 ± 6.07

22.15 ± 0.83

ELISA kit (BioVendor – Laboratorni Medicina a.s., Brno, Czech Republic)

10

Xia [33]

2011

China

NAFLD

40

41

22/18

23/18

68 ± 8.8

69.3 ± 9.3

24.93 ± 3.61

23.71 ± 5.34

ELISA kit (ADL, USA)

NAFLD

+T2DM

44

 

24/20

 

69.2 ± 9.6

 

24.71 ± 5.34

 

11

Yan [34]

2019

China

 

86

56

*b

31/25

45.29 ± 7.35

45.32 ± 7.23

23.55 ± 0.27

23.53 ± 0.25

ELISA kit (Aidibo, Beijing, China)

12

Yilmaz [35]

2011

Turkey

 

54

56

26/28

27/29

47 ± 10

46 ± 11

31.2 ± 4.9

24.9 ± 3.1

ELISA kit (Alpco Diagnostics, Salem, NH, USA)

13

Yu [36]

2012

China

 

43

50

23/20

24/26

55.42 ± 5.87

56.82 ± 5.22

27.48 ± 4.74

22.73 ± 3.01

ELISA kit (Kangtai, Beijing, China)

  1. Abbreviations: M Male, F Female, BMI Body mass index, NAFLD Nonalcoholic fatty liver disease, NASH Nonalcoholic steatohepatitis, SS Simple steatosis, T2DM Type 2 diabetes mellitus
  2. Data are presented as the mean and SD or as the count, as appropriate
  3. *a. Data on the ages of the NAFLD patients in the table do not agree with the data mentioned in the paragraph of the Su 2011 study
  4. *b. There is an obvious error in the original data pertaining to sex for the NAFLD patients in the Yan 2019 study